A Randomized, Double-Blind, Parallel Placebo-Controlled, Single and Multiple Ascending Dose Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Characteristics of Oral DC6001 Tablet in Healthy Chinese Adult Subjects
Latest Information Update: 01 Mar 2026
At a glance
- Drugs DC 6001 (Primary)
- Indications Stargardt disease
- Focus Adverse reactions
- Sponsors Heronova Pharmaceuticals
Most Recent Events
- 01 Mar 2026 New trial record